AstraZeneca’s growth was driven by its portfolio of products in the oncology, biopharmaceuticals and rare disease segments ...

AstraZeneca ( (AZN) ) has released its Q3 earnings. Here is a breakdown of the information AstraZeneca presented to its investors. AstraZeneca ...

AZN beats third-quarter estimates for earnings and sales. It raises its sales and profit outlook for 2024 for the second time ...

Recent health news highlights include Amgen addressing bone density concerns, AstraZeneca revising its financial outlook ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

Oncology Total Revenue (First Nine Months 2024): $16 billion ... Full Year Guidance Upgrade (2024): Total revenue and core ...

The company produces and commercializes medicines for cancer, gastrointestinal, cardiovascular, neuroscience, oncology, respiratory and inflammation and other infectious diseases. Read More on AZN: ...

Susan Galbraith, executive vice president, oncology R&D, AstraZeneca, said: “TROPION-Lung01 was designed to test the potential to improve upon standard-of-care chemotherapy in a broad, previously ...

The adjusted EPS was $2.08 (1 ADR = 2 Common Shares). AstraZeneca’s top business, oncology, increased 19% (up 22% on constant ...

AstraZeneca to invest $3.5 billion in R&D and manufacturing in US: Cambridge, UK Wednesday, November 13, 2024, 09:00 Hrs [IST] AstraZeneca, a global, science-led biopharmaceutical ...

The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...